QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA), a Venlo, Netherlands-based holding firm, acquired Verogen, a San Diego, CA-based firm utilizing next-generation sequencing applied sciences to drive the longer term of human identification and forensic investigation.
The acquisition amounted to $150m in money paid from current reserves. QIAGEN at the moment expects about $20 million of gross sales from the portfolio in 2023, constructing on about $5 million of gross sales for QIAGEN in 2022 from the distribution settlement. Due to deliberate investments for commercialization and portfolio improvement, the transaction is predicted to be dilutive to full-year 2023 adjusted EPS by about $0.03 per share and impartial to adjusted EPS in 2024.
With the acquisition, Qiagen will strengthen its place within the area of Human ID / forensics anchored by pattern assortment and preparation, genetic testing evaluation and workflow automation. The firm additionally beneficial properties entry to Verogen’s GEDmatch database and GEDmatch PRO™ portal. GEDmatch permits customers to add genetic profiles created by different family tree websites with a view to develop the seek for familial hyperlinks; it at the moment comprises greater than 1.8 million genealogical profiles and continues to develop. GEDmatch PRO™ is designed to help police and forensic groups with investigative comparisons to information uploaded by consenting GEDmatch customers.
Led by CEO Brett Williams, Verogen is a devoted developer of DNA-based biometric human identification merchandise for evaluation of forensic genomic samples.
Led by CEO Thierry Bernard, QIAGEN is a supplier of Sample to Insight options that allow prospects to achieve molecular insights from samples containing the constructing blocks of life. Its pattern applied sciences isolates and processes DNA, RNA and proteins from blood, tissue and different supplies. Assay applied sciences make these biomolecules seen and prepared for evaluation. Bioinformatics software program and data bases interpret information to report related, actionable insights. QIAGEN gives options to greater than 500,000 prospects all over the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech corporations) and Academia (life sciences analysis).